Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Equillium Inc(EQ)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for EQ
09/25/2026: EQ (2-star) is currently NOT-A-BUY. Pass it for now.
Equillium Inc is a clinical-stage biotechnology company focused on developing immunomodulatory therapies for autoimmune and inflammatory diseases. Its primary value proposition is its lead asset, Itolizumab, which targets the CD6-ALCAM pathway to address unmet patient needs. While the company benefits from strategic partnerships, it remains a high-risk investment due to the lack of commercial revenue and reliance on clinical trial outcomes. Investors should monitor progress in clinical trials and the potential for additional licensing deals, as the stock is highly sensitive to regulatory news. This company is best suited for growth-oriented investors who can tolerate significant volatility associated with pre-revenue biotech developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward potential based on clinical trial success rather than fundamental revenue growth. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may find opportunity during periods of positive clinical news, provided the trend is bullish. |
| Value investor | Weak fit | As a pre-revenue biotechnology company, traditional valuation metrics like P/E ratios are not applicable. |
| Dividend investor | Weak fit | Equillium does not pay dividends and focuses entirely on re-investing capital into R&D. |
| Low-risk investor | Weak fit | The high volatility and binary nature of clinical outcomes make this stock unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is extremely sensitive to clinical trial outcomes and financing news. |
| Valuation risk | High | Valuations are speculative and tied to unproven future drug success. |
| Competition risk (Biologic/Immunotherapy) | High | Large incumbents have massive R&D budgets and entrenched market positions. |
| Business quality | Medium | The company relies entirely on the successful execution of early-stage science. |
| Dividend income | Low / none | No cash flow exists to support dividend payments. |
| Execution risk | High | Success depends on strict clinical regulatory adherence and trial patient recruitment. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit 372.39% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 105.89M USD | Price to earnings Ratio - | 1Y Target Price 8.56 |
Price to earnings Ratio - | 1Y Target Price 8.56 | ||
Volume (30-day avg) 514.5K shares | Beta 1.8 | 52 Weeks Range 0.76 - 3.54 | Updated Date 09/27/2026 |
52 Weeks Range 0.76 - 3.54 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.09 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development | Clinical trial milestones and potential future commercialization of proprietary therapeutics. | The company currently makes no money; investors are betting on the success of future drug development programs. |
Valuation
Trailing PE - | Forward PE 1.53 | Enterprise Value 54.38M | Price to Sales(TTM) 20.22 |
Enterprise Value 54.38M | Price to Sales(TTM) 20.22 | ||
Enterprise Value to Revenue 21.19 | Enterprise Value to EBITDA 0.07 | Shares Outstanding 63.41M | Shares Floating 36.97M |
Shares Outstanding 63.41M | Shares Floating 36.97M | ||
Percent Insiders 16 | Percent Institutions 65.82 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Equillium Inc
Exchange NASDAQ | Headquarters La Jolla, CA, United States | ||
IPO Launch date 2018-10-11 | Co-Founder, CEO & Director Mr. Bruce Steel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.equilliumbio.com |
Full time employees 14 | Website https://www.equilliumbio.com | ||
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.